Systemic Sclerosis

Immunology·MeSH: Scleroderma, Systemic

Prevalence

30.0 / 100K

27 drugs in development·20 companies·17 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
etorel	GYRE THERAPEUTICS, INC. (GYRE)

Phase 3(4)

Phase 2(9)

Drug	Company
10 mg/kg cm-101	Chemomab Therapeutics Ltd. (CMMB)
hzn-825 bid	AMGEN INC (AMGN)
hzn-825 qd	AMGEN INC (AMGN)
MTX-474	Valneva SE (VALN)
MTX-474	Crinetics Pharmaceuticals, Inc. (CRNX)
rese-cel	Cabaletta Bio, Inc. (CABA)
tibulizumab	Zura Bio Ltd (ZURA)
Vasculan	CUMBERLAND PHARMACEUTICALS INC (CPIX)
Vasculan®	CUMBERLAND PHARMACEUTICALS INC (CPIX)

Phase 1(5)

Drug	Company
ace-1334	ACCELERON PHARMA INC (XLRN)
NKX019	Filana Therapeutics Inc. (FLNA)
prula-cel	Adicet Bio, Inc. (ACET)
rese-cel (resecabtagene autoleucel)	Cabaletta Bio, Inc. (CABA)
vib7734	Viela Bio, Inc. (VIE)

Preclinical(2)

Drug	Company
eb07	Edesa Biotech, Inc. (EDSA)
IRF5 program	ALUMIS INC. (ALMS)

Phase 1/Phase 2(3)

Phase 2/Phase 3(3)

Drug	Company
CABA-201	Cabaletta Bio, Inc. (CABA)
kyv-101	Kyverna Therapeutics, Inc. (KYTX)
standard lymphodepletion regimen	Kyverna Therapeutics, Inc. (KYTX)

BioSniper tracks 27 drugs in development for Systemic Sclerosis across 20 companies.

There are 17 clinical trials targeting Systemic Sclerosis tracked by BioSniper.

The estimated prevalence of Systemic Sclerosis is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.